Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150930 | 0.80 | LMNA (0.41) | MAPK1MCL1OGG1LMNAPSMB8 | |
| SCHEMBL28843681 | 0.77 | CA2 (0.38) | MAPK1MCL1OGG1LMNAPSMB8 | |
| SCHEMBL2092548 | 0.75 | CYP2A6 (0.41) | MAPK1MCL1OGG1LMNAPSMB8 | |
| SCHEMBL8056416 | 0.75 | LMNA (0.40) | MAPK1MCL1OGG1LMNAPSMB8 | |
| SCHEMBL2091918 | 0.75 | CA2 (0.44) | CYP1A2ALDH1A1 | |
| SCHEMBL2094381 | 0.75 | SMN1; SMN2 (0.32) | LMNAMEN1ALDH1A1GAAMAPT | |
| SCHEMBL2090967 | 0.75 | — | — | |
| SCHEMBL17140136 | 0.75 | CTSG (0.35) | CYP1A2CYP2A6TSHRALDH1A1MAPT | |
| SCHEMBL2090743 | 0.75 | CYP2A6 (0.36) | MAPK1MCL1OGG1LMNAPSMB8 | |
| SCHEMBL6002815 | 0.71 | ALDH1A1 (0.39) | MAPK1MCL1OGG1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | claimed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | claimed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-2944633-B1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9637469-B2 | Pyridine derivative | TEIJIN PHARMA LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150284358-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| CN-1440385-A | Pyrrole derivatives for the treatment of AIDS | HOFFMANN LA ROCHE (CH) | 2003-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284358-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | MAPK1 444/4885MCL1 4191/4885OGG1 2607/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAPK1 1392/4885MCL1 3401/4885OGG1 2178/4885 |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | MAPK1 444/4885MCL1 4191/4885OGG1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.